How to access Welireg from the UAE — the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
A UAE patient with von Hippel-Lindau (VHL) disease and associated tumours — renal cell carcinoma, pancreatic neuroendocrine tumours, or central nervous system haemangioblastomas — that do not require immediate surgery may be evaluated by their oncologist for Welireg (belzutifan). Welireg is also FDA-approved for advanced clear-cell renal cell carcinoma (RCC) after prior systemic therapies. Welireg is developed by Merck. In the UAE, Welireg is not yet broadly registered for routine hospital-pharmacy dispensing, which is why your oncologist may be navigating a named-patient import pathway on your behalf.
This guide explains the legal pathway, what documentation your physician needs, typical timing and cost bands, and where Reserve Meds fits in.
The clinical situation
Welireg is a small-molecule inhibitor of hypoxia-inducible factor 2-alpha (HIF-2α), taken as an oral tablet once daily. In VHL disease, it targets the molecular driver downstream of VHL gene loss and can reduce tumour burden across multiple VHL-associated lesions. In advanced RCC, it offers a distinct mechanism after prior VEGF and immune-checkpoint therapies. Eligibility in VHL disease is based on genetic confirmation of VHL and measurable tumour lesions not requiring immediate surgery; in RCC, it is based on prior line history per FDA labeling. Your oncologist will confirm eligibility and set up monitoring — particularly for anaemia and hypoxia, which are on-label class effects.
Is Welireg legally importable into the UAE?
Yes — through the UAE Ministry of Health and Prevention (MoHAP) named-patient import framework. Parallel authority operates in Abu Dhabi through the Department of Health (DoH) and in Dubai through the Dubai Health Authority (DHA), depending on where the prescribing facility is located.
The named-patient mechanism allows a UAE-licensed physician to import a medicine not locally registered when: (a) the medicine is approved by a recognised reference authority such as the US FDA, (b) no clinically equivalent locally registered alternative is suitable, (c) the physician takes clinical responsibility, and (d) chain of custody is documented end to end. For Welireg — an oral therapy with a well-characterised monitoring profile — the pathway is operationally straightforward once the clinical rationale is documented.
How the pathway works, step by step
- Consultation with your treating oncologist or clinical geneticist. For VHL disease, management is often led jointly by an oncologist and a clinical geneticist; the decision to prescribe Welireg is clinical.
- Genetic / diagnostic confirmation. VHL gene confirmation and tumour-imaging documentation, or RCC line history and imaging, is compiled.
- MoHAP named-patient application. Your physician or hospital pharmacy files the application with clinical rationale, patient reference, product details, and chain-of-custody plan.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure Welireg from authorised distribution.
- Ambient shipment. Welireg tablets ship at ambient controlled conditions with chain-of-custody documentation.
- Arrival and dispensing. The hospital pharmacy releases the bottle to the patient with instructions for once-daily dosing and a monitoring schedule (haemoglobin, oxygen saturation, renal function).
What documentation your physician needs
Your physician will typically need to provide:
- A clinical rationale letter confirming VHL-associated tumour burden or advanced RCC, prior therapies where relevant, and Welireg as the indicated treatment
- Verification of their UAE medical licence
- For VHL: genetic testing report confirming VHL mutation
- Patient identifier (anonymised reference where possible)
- Planned dosing schedule and safety monitoring plan (anaemia, hypoxia, renal)
Reserve Meds provides a physician documentation kit that bundles the templates MoHAP reviewers expect to see, including the anaemia/hypoxia surveillance plan that is a standing element for HIF-2α inhibition.
Costs and timing
Welireg's US cash-pay reference price sits in an indicative 2026 range of roughly USD 25,000–30,000 for a 30-day supply, with total course cost driven by duration on therapy. International logistics, MoHAP documentation handling, and concierge coordination add incremental cost. Reserve Meds issues a full transparent quote at the start of intake.
Indicative timing — not guaranteed — for first dispense after cohort intake opens is approximately 10–21 days from the moment a complete MoHAP application is submitted. Refills ship on a rolling basis against your monthly dispensing schedule.
Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.
A culturally-aware note: VHL is a hereditary syndrome, and treatment decisions often involve multiple family members also at genetic risk. Our concierge coordination can include siblings, parents, and adult children in family-education conversations at the patient's direction.
Reserve Meds's role
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Welireg specifically, we provide:
- Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
- Documentation. Regulatory package for your physician and for MoHAP review.
- Logistics. Chain-of-custody shipment coordination to your prescribing hospital pharmacy.
- Concierge case lead. A named point of contact for your family and your physician through intake, first dispense, and refills.
What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating oncologist or clinical geneticist. We operate on a waitlist basis during our pre-launch phase.
Frequently asked
Is this legal in the UAE? Yes, when executed through the MoHAP (or DoH/DHA) named-patient framework with appropriate documentation. Cross-border named-patient import for rare-disease and targeted oncology is a routine mechanism. See our trust and compliance page.
Does VHL require lifetime therapy? Welireg is typically continued while the patient is benefiting and tolerating treatment. Your oncologist will manage dose and duration. Regular imaging and lab monitoring is standard.
My sister also has VHL — can she be evaluated in parallel? Family-member evaluation is clinically appropriate and common in VHL management. Each patient requires their own named-patient application and clinical dossier; our concierge team can coordinate in parallel if that is the family's wish.
What about anaemia on Welireg? Anaemia is a known class effect. Your oncologist monitors haemoglobin and adjusts as needed; supportive treatment (iron, dose adjustment) is part of standard management.
Will private insurance cover this? Cash-pay is the default. Some UAE insurers consider rare-disease and named-patient imports case by case; we supply documentation for your submission but do not process insurance claims directly.
Next step — join the first-cohort waitlist
Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we are ready to enter intake for Welireg coordination in the UAE.
Add me to the Welireg waitlistComposite case examples. Reserve Meds is in pre-launch. This content is for general information and does not constitute medical advice.
Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.